par Verset, Gontran ;Verslype, Chris;Reynaert, Herwig;Borbath, Ivan;Langlet, Philippe ;Vandebroek, A;Peeters, Michel ;Houbiers, Ghislain;Francque, S;Arvanitakis, Marianna ;Van Laethem, Jean-Luc
Référence British Journal of Cancer, 97, 5, page (582-588)
Publication Publié, 2007-09
Référence British Journal of Cancer, 97, 5, page (582-588)
Publication Publié, 2007-09
Article révisé par les pairs
Titre: |
|
Auteur: | Verset, Gontran; Verslype, Chris; Reynaert, Herwig; Borbath, Ivan; Langlet, Philippe; Vandebroek, A; Peeters, Michel; Houbiers, Ghislain; Francque, S; Arvanitakis, Marianna; Van Laethem, Jean-Luc |
Informations sur la publication: | British Journal of Cancer, 97, 5, page (582-588) |
Statut de publication: | Publié, 2007-09 |
Sujet CREF: | Sciences bio-médicales et agricoles |
Mots-clés: | Hepatocellular carcinoma (HCC) |
Octreotide | |
Somatostatin analogues | |
Tamoxifen | |
MeSH keywords: | Adult |
Aged | |
Aged, 80 and over | |
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use | |
Carcinoma, Hepatocellular -- drug therapy -- metabolism -- pathology | |
Diarrhea -- chemically induced | |
Female | |
Humans | |
Liver Neoplasms -- drug therapy -- metabolism -- pathology | |
Male | |
Middle Aged | |
Multivariate Analysis | |
Nausea -- chemically induced | |
Neoplasm Staging | |
Octreotide -- administration & dosage -- adverse effects | |
Patient Compliance -- statistics & numerical data | |
Prognosis | |
Quality of Life | |
Survival Analysis | |
Tamoxifen -- administration & dosage -- adverse effects | |
Treatment Outcome | |
alpha-Fetoproteins -- metabolism | |
Note générale: | Clinical Trial, Phase III |
Journal Article | |
Multicenter Study | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0007-0920 |
info:doi/10.1038/sj.bjc.6603901 | |
info:pii/6603901 | |
info:scp/34548356811 | |
info:pmid/17687341 | |
PMC2360361 |